<h1>Pharma Company Acquires UDENYCA® Biosimilar Pegfilgrastim to Boost Global Biosimilar Portfolio and Market Access</h1> A pharmaceutical company and its global subsidiaries acquired UDENYCA®, a biosimilar pegfilgrastim product from another biopharmaceutical company, enhancing their position as a leading global supplier in the biosimilar market. The acquisition expands their FDA-approved portfolio and strengthens their presence in the U.S. and international markets. The product is indicated to reduce infection risk in patients undergoing certain cancer treatments and offers multiple administration options. The transaction included the transfer of key employees to ensure continuity of supply and commercialization. Legal counsel was provided by a law firm specializing in such transactions. The product carries specific contraindications, warnings, and potential adverse effects, and patients using the on-body injector are advised to monitor for device performance issues. This acquisition supports the purchaser's strategic growth and commitment to increasing patient access to biosimilar therapies.